Enteris Begins Its Phoenix Story With Nordic Deal
This article was originally published in The Pink Sheet Daily
Newly formed Enteris inks its first licensing deal as it tries to prove to potential partners that its technology can help company up-cycle old drugs and improve their patent life by making them orally available.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.